CD28 and acute lymphoblastic leukemia: There are multifactorial potential interactions between T-ALL and stroma that shape the myeloid anti-tumor immune response, including between CD47/SIRPα, PD-L1/PD-1, CD40/CD40L, and CD28/CD80/86.